vedolizumab

Type: Keyphrase
Name: vedolizumab
First reported Oct 28 2014 - Updated Oct 28 2014 - 1 reports

AGW honours Melbourne gastroenterologist

Gut bacteria and immunological therapies are among the most promising avenues for IBD research, says Professor Michael Kamm, who has been honoured with the 2014 Distinguished Research Award from the Gastroenterological Society of Australia.“It would be ... [Published Gastroenterology Update - Oct 28 2014]
First reported Oct 23 2014 - Updated Oct 24 2014 - 2 reports

Added benefit of vedolizumab is not proven -- ScienceDaily

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ... [Published DailyMe.Com - Oct 24 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Patients who lost response to vedolizumab achieved disease activity improvement with increased dose frequency

PHILADELPHIA — Marla C. Dubinsky, MD, chief of pediatric gastroenterology and hepatology, and co-director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, the Icahn School of Medicine at Mt. Sinai Hospital in NY, discusses ... [Published Orthopedics Today - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Tip: Note latest APCs added to I/OCE

CMS added these four APCs in the latest I/OCE update, effective October 1: 1487, injection, testosterone undecanoate, 1 mg, assigned to HCPCS C9023 1488, injection, ramucirumab, 5 mg, assigned to HCPCS C9025 1489, injection, vedolizumab, ... [Published HCPro - Oct 17 2014]
First reported Oct 09 2014 - Updated Oct 10 2014 - 1 reports

Crohn’s Disease and Remission with Vedolizumab - IBD in the News

<a style="font-size: 15px; font-weight: bold;font-decoration: none;" href="http://www.youtube.com/watch?v=kZ1hppMNyTQ&feature=youtube_gdata"&gt;Crohn’s Disease and Remission with Vedolizumab - IBD in the News Edward Loftus Jr., M.D., a gastroenterologist ... [Published Mayo Clinic - YouTube - Oct 09 2014]
First reported Oct 06 2014 - Updated Oct 06 2014 - 1 reports

Takeda to present phase III data for Crohn's and colitis treatment

:59 in Pharmaceutical Company Product News Takeda has confirmed it will present data relating to the performance of its Entyvio treatment for ulcerative colitis and Crohn's disease during the 21st United European Gastroenterology Week in Vienna, which ... [Published Zenopa - Oct 06 2014]
First reported Oct 02 2014 - Updated Oct 03 2014 - 2 reports

Takeda releases interim Phase III data supporting long-term efficacy of vedolizumab

Takeda Pharmaceuticals International has reported new data from GEMINI LTS (Long-Term Safety), an ongoing, open-label extension Phase III trial of Entyvio (vedolizumab) to treat adults with moderately to severely active ulcerative colitis (UC) and Crohn's ... [Published PBR - News - Oct 03 2014]
First reported Oct 02 2014 - Updated Oct 02 2014 - 1 reports

Surveyed gastroenterologists likely to prescribe Entyvio to IBD patients

Most surveyed gastroenterologists were familiar with vedolizumab as an FDA-approved treatment alternative for patients with inflammatory bowel disease and anticipated prescribing it to their patients within 1 year, according to a Decision Resources Group ... [Published Orthopedics Today - Oct 02 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 2 reports

The Majority of Surveyed Gastroenterologists Have a Positive Reaction to Takeda's Cell Adhesion Molecule Inhibitor Entyvio

Other key findings from the report entitled LaunchTrends: Entyvio (vedolizumab) Wave 1 (U.S.):Comments from Decision Resources Group Analyst Adi ReskeAbout Decision Resources Group Decision Resources Group offers best-in-class, high-value information ... [Published Pettinga Financial Advisors - Sep 29 2014]
First reported May 26 2014 - Updated May 28 2014 - 2 reports

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ... [Published PRESSEMITTEILUNGEN - May 27 2014]
First reported May 20 2014 - Updated May 21 2014 - 3 reports

Takeda's Entyvio gets FDA approval to treat ulcerative colitis, Crohn's disease

Japan-based Takeda Pharmaceutical Company (Takeda) and its wholly-owned subsidiary Takeda Pharmaceuticals USA have received approval from the US Food and Drug Administration (FDA) for a new biologic therapy, Entyvio (vedolizumab), to treat adults with ... [Published PBR - News - May 21 2014]
First reported May 20 2014 - Updated May 21 2014 - 2 reports

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration ... [Published PR Newswire: Policy & Public Interest - May 20 2014]

Quotes

"This will be a fantastic meeting," Dr. Sarles said. "Everything in it is clinical, it's translatable immediately into practice, and members and nonmembers alike will have network and fellowship opportunities and a chance to see where the profession has been, where it is today, and where it's going. It's my favorite meeting of the year, but thenthen again, I'm obviously biased."
...long-term safety data are available, PML will remain a concern among some gastroenterologists, constraining Entyvio use as a first-line biologic. "High opportunity exists for emerging therapies in the inflammatory bowel disease market. Improved efficacy in the acute and maintenance setting, long-term safety and more convenient dosing formulations are the highly desired attributes for products in development for UC and CD."
..." 25% of US adults consult online physician-rating sites - Doctors Check Online Ratings From Patients and Make Changes. Online ratings "can be pretty brutal. However, part of being a physician now is having to deal with these.” "When we decided to quit ignoring it and embraced it, it totally changed the game" - WSJ http://buff.ly/1mQ5XLC FDA Approves New Drug for Crohn Disease and UC: vedolizumab (Entyvio) , an injectable monoclonal antibody. Vedolizumab, an integrin receptor antagonist http://buff.ly/1lFuRtv Interferon-free regimen with 3 drugs effective in Hep C with Cirrhosis (ABT-450/r–Ombitasvir, Dasabuvir, Ribavirin) http://buff.ly/1o8pDMS -- Combination of nucleotide polymerase inhibitor sofosbuvir and antiviral ribavirin effective in HCV Genotypes 2 and 3 http://buff.ly/1o8pWr1 The relative risk reduction of 20% in breast-cancer mortality associated with mammography comes at a price. Abolish Mammography Screening Programs, says the SwissSwiss Medical Board. The report caused an uproar http://buff.ly/1o8qgGo In obese patients with uncontrolled DM2, intensive medical therapy plus bariatric surgery was better than drugs alone http://buff.ly/1o8qD3G First dialysis machine was made with aluminium from a bomber that was shot down and bits from an automobile engine http://buff.ly/1om861k At least 10% of adults and nearly all children who receive renal-replacement therapy have an inherited kidney disease http://buff.ly/1n8078E Kidney disease in farming communities worldwide remains a mystery : heavy metals and pesticides? indigenous herbs? OTC pain killers? chronic dehydration? http://buff.ly/1n80qjy Worldwide, chronic kidney disease affects 8—16% of population , number of deaths almost doubled in the past decade http://buff.ly/1n80MHa The articles were selected from Twitter and my RSS subscriptions. Please feel free to send suggestions for articles to clinicalcases AT gmail.com and you will receive acknowledgement in the next edition of this publication. "
"With the development of vedolizumab, Takeda is building upon this heritage and expanding into innovative therapies with a new biologic treatment" Smith said

More Content

All (27) | News (14) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
AGW honours Melbourne gastroenterologist [Published Gastroenterology Update - Oct 28 2014]
Added benefit of vedolizumab is not proven -- S... [Published DailyMe.Com - Oct 24 2014]
Added benefit of vedolizumab is not proven [Published Press News.org - Oct 23 2014]
Patients who lost response to vedolizumab achie... [Published Orthopedics Today - Oct 20 2014]
Tip: Note latest APCs added to I/OCE [Published HCPro - Oct 17 2014]
Conference to Headline 'Remarkable Success' in ... [Published General Medicine eJournal - Oct 10 2014]
Crohn’s Disease and Remission with Vedolizumab ... [Published Mayo Clinic - YouTube - Oct 09 2014]
Takeda to present phase III data for Crohn's an... [Published Zenopa - Oct 06 2014]
Takeda releases interim Phase III data supporti... [Published PBR - News - Oct 03 2014]
Surveyed gastroenterologists likely to prescrib... [Published Orthopedics Today - Oct 02 2014]
Takeda presents Phase III data for Entyvio in U... [Published Pharma Letter - Oct 02 2014]
The Majority of Surveyed Gastroenterologists Ha... [Published Pettinga Financial Advisors - Sep 29 2014]
The Majority of Surveyed Gastroenterologists Ha... [Published CBS Detroit - Sep 29 2014]
Entyvio (Crohn’s Disease) therapeutics Market I... [Published MyNewsDesk - Sep 24 2014]
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
May's top stories: Bayer's $14.2bn Merck deal, ... [Published Pharmaceutical Technology - Jun 06 2014]
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Takeda's Entyvio gets FDA approval to treat ulc... [Published PBR - News - May 21 2014]
Entyvio Approved for Ulcerative Colitis and Cro... [Published Yahoo! Health News - May 21 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published PR Newswire: Policy & Public Interest - May 20 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published Nycomed News RSS feed - May 20 2014]
Takeda's Entyvio Wins FDA OK for Severe Colitis [Published MedPageToday.com - medical news plus CME for ph ... - May 20 2014]
EMA committee issues positive opinion for Taked... [Published Pharmaceutical Business Review - Mar 24 2014]
Crohn's Disease Market to Show Modest Growth to... [Published Pharmaceutical Executive - Feb 04 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Crohn’s Disease and Remission with Vedolizumab ... [Published Mayo Clinic - YouTube - Oct 09 2014]
<a style="font-size: 15px; font-weight: bold;font-decoration: none;" href="http://www.youtube.com/watch?v=kZ1hppMNyTQ&feature=youtube_gdata"&gt;Crohn’s Disease and Remission with Vedolizumab - IBD in the News Edward Loftus Jr., M.D., a gastroenterologist ...
Takeda releases interim Phase III data supporti... [Published PBR - News - Oct 03 2014]
Takeda Pharmaceuticals International has reported new data from GEMINI LTS (Long-Term Safety), an ongoing, open-label extension Phase III trial of Entyvio (vedolizumab) to treat adults with moderately to severely active ulcerative colitis (UC) and Crohn's ...
Top medicine articles for July 2014 [Published Clinical Cases and Images: CasesBlog - Jul 23 2014]
A collection of some interesting medical articles published recently: Migraines Linked to Increased Risk of 'Silent Strokes' http://buff.ly/1hTE5Ru Doctor’s Salaries Are Not the Big Cost - NYTimes http://buff.ly/QWe2lx  -- "There is a startling ...
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ...
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.